A meta-analysis of the role of p38 mitogen-activated protein kinase inhibitors in patients with active rheumatoid arthritis

Clinical Rheumatology

Volumn 32, Issue 12, 2013, Pages 1697-1702

  Li, Lan ^a   Li, Guogang ^a   Yu, Chaohui ^a   Li, Youming ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Meta analysis; p38 Mitogen activated protein kinase inhibitors; Rheumatoid arthritis

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PAMAPIMOD; PLACEBO; TALMAPIMOD; VX 702;

COMPARATIVE STUDY; DAS28; DIARRHEA; DISABILITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEADACHE; HEART DISEASE; HOSPITALIZATION; HUMAN; INFECTION; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; METHOTREXATE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84890441590     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2340-1     Document Type: Review

References (19)

1. Choy E (2012) Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 51(Suppl 5):v3-v11
2. Keith MP, Edison JD, Gilliland WR (2012) Progress toward personalized treatment of rheumatoid arthritis. Clin Pharmacol Ther 92(4):440-442
3. Malemud CJ, Miller AH (2008) Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs. Expert Opin Ther Targets 12(2):171-183
4. Thalhamer T, McGrath MA, Harnett MM (2008) MAPKs and their relevance to arthritis and inflammation. Rheumatology 47(4):409-414
5. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW et al (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372(6508):739-746
6. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H (2003) Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 48(9):2670-2681
7. Amakye D, Tong S, Ward C, Beazley W (2004) Pharmacokinetics (PK) and pharmacodynamics (PD) of SCIO-469, a p38a MAP kinase inhibitor. Clin Pharmacol Ther 75:P54
8. Hill RJ, Dabbagh K, Phippard D, Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning AM, Peng SL, Goldstein DM, Wong BR (2008) Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 327(3):610-619
9. Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, Caulfield JP (2009) Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 60(2):335-344
10. Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135(11):982-989
11. Alten RE, Zerbini C, Jeka S, Irazoque F, Khatib F, Emery P, Bertasso A, Rabbia M, Caulfield JP (2010) Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis 69(2):364-367
12. Damjanov N, Kauffman RS, Spencer-Green GT (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 60(5):1232-1241
13. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE (2011) A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 38(5):846-854
14. Zhang X, Huang Y, Navarro MT, Hisoire G, Caulfield JP (2010) A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 50(9):1031-1038
15. Cheriyan J, Webb AJ, Sarov-Blat L, Elkhawad M, Wallace SM, Mäki-Petäjä KM, Collier DJ, Morgan J, Fang Z, Willette RN, Lepore JJ, Cockcroft JR, Sprecher DL, Wilkinson IB (2011) Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 123(5):515-523
16. van Westerloo DJ, Rauws EA, Hommes D, de Vos AF, van der Poll T, Powers BL, Fockens P, Dijkgraaf MG, Bruno MJ (2008) Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence. Gastrointest Endosc 68(2):246-254
17. Weisman M, Furst D, Schiff M, Kauffman R, Merica E, Martin-Munley S, et al. (2002) A double-blind, placebo-controlled trial of VX-745, an oral p38 mitogen activated protein kinase (MAPK) inhibitor, in patients with rheumatoid arthritis (RA) [abstract]. Presented at the 2002 annual European Congress of Rheumatology; Stockholm, Sweden. Abstract FRI0018. URL: http://www.eular.org. Accessed 12 June 2002
18. Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, Winter T, Meier U, Yong C, Steffgen J, BIRB 796 Study Group (2006) Oral p38 mitogenactivated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4(3):325-334
19. Tong SE, Daniels SE, Nontano T, Chang S, Desjardins P (2004) Scio-469, a novel p38α MAPK inhibitor, provides efficacy in acute post-surgical dental pain. Clin Pharmacol Ther 75(2):P3-P3